Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog and search the HCV drug pipeline click here; for more information on HCV clinical trials click here

Be sure to check out our other blog: Hepatitis & Tattoos

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Wednesday, March 21, 2012

Marker of Active Hep B Infection Declines in Those Coinfected with HIV, Treated with Tenofovir

Prolonged therapy with antiretroviral regimens containing tenofovir is associated with a decline in hepatitis B surface antigen (HBsAg) levels in people coinfected with HIV and hepatitis B virus (HBV), according to a report presented by Dutch researchers at the 19th Conference on Retroviruses and Opportunistic Infections on Tuesday, March 6, in Seattle.

Loss of HBsAg is the ultimate chronic HBV infection treatment goal, as it signals that the immune system has ramped up and gained control of HBV replication. Among people with chronic HBV infection who experience a spontaneous loss in HBsAg, rates of cirrhosis and liver cancer are significantly lower than those who remain positive for the antigen, considered to be one of the most important markers of active infection.

Read more....
Posted by at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)